Dementias Platform UK (DPUK) forms a central pillar in the delivery of the UK Prime Minister’s dementia challenge. DPUK is developing an integrated research environment enabling rapid data analyses and a new generation of highly targeted, highly informative discovery studies and early phase trials; positioning the UK as world leading location for dementia research.
DPUK has a strong global voice, connected and integrated within the dementia research ecosystem in Europe and beyond. DPUK facilitates data integration and harmonisation across studies to support data sharing, DPUK supports the development of standardised cognitive assessment suitable for use in large-scale population studies and trials. DPUK welcomes opportunities for international collaboration.
Below are some of the international organisations with which DPUK is connected.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease. ADNI researchers collect, validate and utilize data such as MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors for the disease. Data from the North American ADNI’s study participants, including Alzheimer’s disease patients, mild cognitive impairment subjects and elderly controls. Professor Weiner, Principal Investigator ADNI, recently presented their work at the DPUK Conference 2016.
The Canadian Consortium on Neurodegeneration in Aging (CCNA) provides the infrastructure and support that facilitates collaboration amongst Canada’s top dementia researchers. By accelerating the discovery, innovation, and the adoption of new knowledge, the CCNA positions Canada as a global leader in increasing understanding of neurodegenerative diseases, working towards prevention, and improving the quality of life of those living with dementia. CCNA became a formal collaborator with DPUK in April 15.
The Canadian Longitudinal Study on Aging (CLSA) is a large, national, long-term study of more than 50,000 men and women who were between the ages of 45 and 85 when recruited. These participants will be followed until 2033 or death. The aim of the CLSA is to find ways to help us live long and live well, and understand why some people age in healthy fashion while others do not. CSLA became a formal collaborator with DPUK in July 2016.
CoEN is an international initiative involving research funders in the UK, Canada, Germany, Belgium, Ireland, Italy, Slovakia and Spain. The aim of the initiative is to encourage collaborative research between recognised national centres of excellence in neurodegeneration in order to accelerate progress in understanding of the disease as well as the identification of new therapeutic approaches. DPUK population studies and researchers are active participants in CoEN programmes and the recipients of several CoEN awards.
EMIF is a European initiative that aims to develop a common information framework of patient data to open up new avenues of research for scientists. DPUK works alongside EMIF, helping to advance statistical analyses of information across population studies (cohorts). DPUK has based its meta data catalogue on the EMIF Alzheimer’s disease fingerprint. DPUK collected cohort meta data utilising an adapted version of the EMIF Alzheimer’s disease fingerprint.
GAAIN is a data gateway facilitating access to a wide range of population and clinical datasets. DPUK is complementary to GAAIN in also enabling access to multiple independent datasets. In addition DPUK offers a secure data analysis space to make it easier for allow researchers to interrogate these data. DPUK looks forward to working with GAAIN to promote international data sharing.
The GAP Foundation is joining together leading academic researchers, pharmaceutical companies, nonprofit organizations and foundations, and governments around the world to reduce the time, cost and risk of Alzheimer’s clinical trials in order to speed innovative medicines to those with or at risk of Alzheimer’s disease.
The GAP Foundation is establishing a standing global trial-ready platform to drive quality, efficiency, and innovation in Alzheimer’s Clinical Trials, seeking to reduce clinical testing cycle times by two years or more and to achieve greater uniformity in trial populations. It is doing that by building large, well-characterized trial-ready cohorts, a network of certified high-performance clinical trial sites, and an adaptive proof-of-concept trial mechanism.
IMI is one of Europe’s largest public-private initiatives which aims to speed up the development of better and safer medicines for patients. DPUK is a strong contributor to the IMI European Prevention of Alzheimer’s Dementia Initiative (EPAD), which will establish a European-wide register of 24,000 study participants, of which 1,500 will be invited to participate in trials to test new treatments for prevention of Alzheimer’s.
The National Institute for Health Research (NIHR) is funded through the Department of Health to improve the health and wealth of the nation through research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. The Deep and Frequent Phenotyping study is funded by the National Institute of Health Research (NIHR) and the Medical Research Council (MRC).
JPND is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases. DPUK population studies and researchers are active participants in JPND programmes and the recipients of several JPND awards. DPUK strongly supports the cross-border collaborative goals of the JPND and CoEN initiatives.
OECD promotes policies that will improve the economic and social well-being of people around the world. DPUK is plugged into OECD global Open Science and Big Data initiatives. DPUK has signed a transatlantic collaboration agreement with the Canadian Collaboration for Neurodegeneration and Aging (CCNA) to share data and research expertise in the fight to better understand, treat and prevent dementia.
The World Dementia Council emerged following the G8 dementia summit in December 2013. The Council aims to stimulate global innovation, development and commercialisation of life enhancing drugs, treatments and care for people with dementia, or at risk of dementia, within a generation. As an innovative partnership between academics and industry, DPUK’s own mission chimes with the ambitions of the Council, with our programme of discovery studies and early phase trials and goals to accelerate the development of new compounds for dementia. Dr Dennis Gillings, the World Dementia Envoy recorded a message of support for DPUK’s official launch conference in October 2015.